Voyager Therapeutics: Pfizer Exercises One of Two Capsid Options
October 04 2022 - 7:59AM
Dow Jones News
By Colin Kellaher
Voyager Therapeutics Inc. on Tuesday said Pfizer Inc. exercised
one of two options to license a novel capsid generated from its
Tracer capsid discovery platform, letting the second option
lapse.
The Cambridge, Mass., gene-therapy company said Pfizer's
exercise of the option targeting an undisclosed rare neurologic
disease triggers a $10 million payment from the New York
drugmaker.
Last October, Voyager said it had inked an agreement with Pfizer
for the two options, targeting central-nervous-system and
cardiovascular diseases. Voyager received $30 million upfront and
was eligible for up to $20 million in exercise fees, as well as up
to $580 million in potential milestone payment.
Voyager said it remains eligible for up to $290 million in
milestone payments related to the neurologic disease, while all
rights to the capsid for a cardiovascular disease target revert to
the company.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 04, 2022 07:44 ET (11:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024
